Abstract: This application describes novel therapeutic strategies for treating patients with hypertriglyceridemia and/or chylomicronemia based on the presence of GPIHBP1 autoantibodies. It was unexpectedly found that autoantibodies to GPIHBP1, a GPI anchored protein of capillary endothelial cells that shuttles lipoprotein lipase to its site of action in the capillary lumen, were found to be present in patients with hypertriglyceridemia, and that the autoantibodies blocked the binding of lipoprotein lipase (LPL) to GPIHBP1. Patients having hypertriglyceridemia and/or chylomicronemia and also having GPIHBP1 autoantibodies may be treated with a therapeutically effective amount of an immunosuppressive treatment and/or GPIHBP1 activator.

Abstract: The current disclosure relates to a novel therapeutic strategy for patients with hypertriglyceridemia and/or chylomicronemia, wherein the patient is determined to have autoantibodies to GPIHBP1. It was unexpectedly found that autoantibodies to GPIHBP1, a GPI anchored protein of capillary endothelial cells that shuttles lipoprotein lipase to its site of action in the capillary lumen, were found to be present in patients with hypertriglyceridemia, and that the autoantibodies blocked the binding of lipoprotein lipase (LPL) to GPIHBP1. Accordingly, aspects of the disclosure relate to a method for treating hypertriglyceridemia and/or chylomicronemia in a patient comprising administering a therapeutically effective amount of an immunosuppressive treatment and/or GPIHBP1 activator to the patient; wherein the patient has been determined to have GPIHBP1 autoantibodies.